| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other expense | -191,974 | -981,674 | -122,505 | -388,465 |
| Loss before income taxes | -578,503 | -1,451,187 | -668,564 | -1,196,923 |
| Net loss | -578,503 | -1,451,187 | -668,564 | -1,196,923 |
| Net loss per share, basic | -0.36 | -0.9 | -0.42 | -0.94 |
| Net loss per share, diluted | -0.36 | -0.9 | -0.42 | -0.94 |
| Weighted average number of shares outstanding, basic | 1,605,377 | 1,605,377 | 1,605,377 | 1,268,795 |
| Weighted average number of shares outstanding, diluted | 1,605,377 | 1,605,377 | 1,605,377 | 1,268,795 |
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)